272 related articles for article (PubMed ID: 17170721)
21. Methotrexate-related neurotoxicity in the treatment of childhood acute lymphoblastic leukemia.
Shuper A; Stark B; Kornreich L; Cohen IJ; Avrahami G; Yaniv I
Isr Med Assoc J; 2002 Nov; 4(11):1050-3. PubMed ID: 12489505
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
23. Whole brain magnetization transfer histogram analysis of pediatric acute lymphoblastic leukemia patients receiving intrathecal methotrexate therapy.
Yamamoto A; Miki Y; Adachi S; Kanagaki M; Fushimi Y; Okada T; Kobayashi M; Hiramatsu H; Umeda K; Nakahata T; van Buchem MA; Togashi K
Eur J Radiol; 2006 Mar; 57(3):423-7. PubMed ID: 16314063
[TBL] [Abstract][Full Text] [Related]
24. Outcome of acute lymphoblastic leukemia in children with AL90 regimen: impact of response to treatment and sex difference on prognostic factors.
Ishii E; Eguchi H; Matsuzaki A; Koga H; Yanai F; Kuroda H; Kawakami K; Ayukawa H; Akiyoshi K; Kamizono J; Tamai Y; Kinukawa N; Okamura J
Med Pediatr Oncol; 2001 Jul; 37(1):10-9. PubMed ID: 11466717
[TBL] [Abstract][Full Text] [Related]
25. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia.
Thompson PA; Murry DJ; Rosner GL; Lunagomez S; Blaney SM; Berg SL; Camitta BM; Dreyer ZE; Bomgaars LR
Cancer Chemother Pharmacol; 2007 May; 59(6):847-53. PubMed ID: 17136402
[TBL] [Abstract][Full Text] [Related]
26. [Accretion of bone mass in patients treated for childhood acute lymphoblastic leukemia].
Muszyńska-Rosłan K; Konstantynowicz J; Krawczuk-Rybak M
Pol Merkur Lekarski; 2007 Oct; 23(136):271-5. PubMed ID: 18293849
[TBL] [Abstract][Full Text] [Related]
27. Early and delayed consolidation chemotherapy significantly improves the outcome of children with intermediate risk acute lymphoblastic leukemia. Final results of the prospective randomized PETHEMA ALL-89 TRIAL.
Ortega JJ; Ribera JM; Oriol A; Bastida P; González ME; Calvo C; Egurbide I; Hernández Rivas JM; Rivas C; Alcalá A; Besalduch J; Maciá J; Gardella S; Carnero M; Lite JM; Casanova F; Martinez M; Fontanillas M; Feliu E; San Miguel JF;
Haematologica; 2001 Jun; 86(6):586-95. PubMed ID: 11418367
[TBL] [Abstract][Full Text] [Related]
28. Methotrexate infusions as central nervous system prophylaxis in children with acute lymphocytic leukemia: the Norwegian experience.
Moe PJ; Holen A; Nygaard R; Glomstein A; Madsen B; Hellebostad M; Stokland T; Wefring KW; Steen-Johnsen J; Nielsen B; Hapnes C; Børsting S
Pediatr Hematol Oncol; 2003; 20(3):187-200. PubMed ID: 12637215
[TBL] [Abstract][Full Text] [Related]
29. Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Heyman M; Kristinsson J; Mogensen UB; Rosthøj S; Vettenranta K; Wesenberg F; Saarinen-Pihkala U;
J Pediatr Hematol Oncol; 2009 Jun; 31(6):385-92. PubMed ID: 19648786
[TBL] [Abstract][Full Text] [Related]
30. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
[TBL] [Abstract][Full Text] [Related]
31. [Adverse effects of methotrexate in the treatment of acute lymphoblastic leukemia in Uyghur and Han children].
Hu WW; Nuriding H; Yan M
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Nov; 14(11):852-5. PubMed ID: 23146734
[TBL] [Abstract][Full Text] [Related]
32. [Correlation study of blood drug concentration and nephrotoxicity on high dose methotrexate therapy in suggestion of diagnosis and treatment of childhood acute lymphoblastic leukemia in the 4th revised edition].
Cheng DH; Lu H; Zou XQ
Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):771-774. PubMed ID: 29050116
[No Abstract] [Full Text] [Related]
33. [Influence of thymidylate synthase gene polymorphisms on high-dose methotrexate-related toxicities in childhood acute lymphoblastic leukemia].
Zhu XJ; He XL; Wu YP; Zou RY; Li WL; Zou H; You YL; Liu H; Tian X
Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jan; 17(1):11-4. PubMed ID: 25616285
[TBL] [Abstract][Full Text] [Related]
34. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
[TBL] [Abstract][Full Text] [Related]
36. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia.
Maiguma T; Hayashi Y; Ueshima S; Kaji H; Egawa T; Chayama K; Morishima T; Kitamura Y; Sendo T; Gomita Y; Teshima D
Int J Clin Pharmacol Ther; 2008 Nov; 46(11):584-90. PubMed ID: 19000557
[TBL] [Abstract][Full Text] [Related]
37. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
[TBL] [Abstract][Full Text] [Related]
38. Cognitive sequelae of treatment in childhood acute lymphoblastic leukemia: cranial radiation requires an accomplice.
Waber DP; Tarbell NJ; Fairclough D; Atmore K; Castro R; Isquith P; Lussier F; Romero I; Carpenter PJ; Schiller M
J Clin Oncol; 1995 Oct; 13(10):2490-6. PubMed ID: 7595698
[TBL] [Abstract][Full Text] [Related]
39. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.
Bhojwani D; Sabin ND; Pei D; Yang JJ; Khan RB; Panetta JC; Krull KR; Inaba H; Rubnitz JE; Metzger ML; Howard SC; Ribeiro RC; Cheng C; Reddick WE; Jeha S; Sandlund JT; Evans WE; Pui CH; Relling MV
J Clin Oncol; 2014 Mar; 32(9):949-59. PubMed ID: 24550419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]